PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company’s website.

As part of the CEO Corner segment, Pankaj Mohan, Ph.D., Founder and Chief Executive Officer of Sonnet, highlighted the Company’s key accomplishments for calendar year 2024 and the targeted value-driving milestones in calendar year 2025.

The CEO Corner is now accessible on the Company’s website here. Segments on the CEO Corner platform will be accessible on the Company’s website (www.sonnetbio.com) for 90 days.

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as F_HAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's F_HAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. F_HAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.

Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
This email address is being protected from spambots. You need JavaScript enabled to view it.